Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002318365 | SCV000851791 | likely pathogenic | Inborn genetic diseases | 2017-05-25 | criteria provided, single submitter | clinical testing | The p.G879A variant (also known as c.2636G>C), located in coding exon 15 of the SCN2A gene, results from a G to C substitution at nucleotide position 2636. The glycine at codon 879 is replaced by alanine, an amino acid with similar properties. This variant has been determined to be the result of a de novo mutation or germline mosaicism in one family tested in our laboratory with an isolated case of SCN2A-related epilepsy. A different alteration, located at the same position, p.G879R (c.2635G>A), was detected as de novo in an individual with early infantile epileptic encephalopathy type 11 (EIEE11) (Soden SE et al. Sci Transl Med, 2014 Dec;6:265ra168).This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |